Caribou Biosciences (CRBU) has issued an announcement.
Caribou Biosciences, Inc. has released promising updates on the ANTLER Phase 1 trial of their anti-CD19 CAR-T cell therapy, CB-010, for patients with relapsed or refractory B cell non-Hodgkin lymphoma. Engaging discussions with key opinion leaders and management were part of a webcast on the data, all of which is accessible through the Company’s website. Investors and interested parties can look forward to a detailed presentation at the upcoming ASCO Annual Meeting.
See more insights into CRBU stock on TipRanks’ Stock Analysis page.
